Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

Trial Profile

Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Doxorubicin (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 29 Dec 2016 Status changed from recruiting to completed.
    • 01 Oct 2015 New trial record
    • 29 Sep 2015 According to an Eisai media release, additional approval has been received for the vascular embolization device DC Bead to be used for the treatment of hypervascular tumors and arteriovenous malformations in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top